AC
CLVS

Athanor Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

Athanor Capital’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,415
Closed -$94K – 914
2021
Q1 		$94K Sell
13,415
-976
-7% -$6.54K ﹤0.01% 786
2020
Q4 		$69K Buy
+14,391
New +$72.8K ﹤0.01% 687

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Athanor Capital's CLVS Position: Q2 2021 in Review

Athanor Capital sold out of Clovis Oncology, Inc. (CLVS) in Q2 2021, closing a stake of 13,415 shares — an estimated $94K sold.

Athanor Capital first reported a position in CLVS in Q4 2020 and held it in 2 quarters. The position peaked at $94K in Q1 2021. 160 funds tracked by Wall St. Rank hold CLVS as of Q2 2021.

  • Athanor Capital reported no remaining Clovis Oncology, Inc. position as of Q2 2021 after selling out during the quarter.
  • Athanor Capital sold 13,415 Clovis Oncology, Inc. shares in Q2 2021, an estimated $94K.
  • Athanor Capital first reported a position in Clovis Oncology, Inc. in Q4 2020 and held it in 2 quarters.
  • Athanor Capital's Clovis Oncology, Inc. position peaked at $94K in Q1 2021.
  • 160 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.